Prelude Therapeutics

Prelude Therapeutics

Prelude Therapeutics

Prelude Therapeutics is a developer of novel therapies intended to target key drivers of cancer cell growth, survival and resistance.
Founded
2016
Raised
$50M
Follow us
Latest funding
$50,000,000
Venture capital (Series C) - 2020
OrbiMed Advisors Fidelity Management & Research Company
Team Size
1–10
Employees
$50,000,000 Venture capital (Series C)
Technical.ly Delaware

Prelude Therapeutics just raised a $50M Series C